Istiratumab
Modify Date: 2024-04-03 17:27:38
Istiratumab structure
|
Common Name | Istiratumab | ||
|---|---|---|---|---|
| CAS Number | 1509928-04-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IstiratumabIstiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3]. |
| Name | Istiratumab |
|---|
| Description | Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Istiratumab (500 nM，24 小时) 在人胰腺癌细胞系中抑制 IGF-1 和 HRG 共刺激引起的AKT 激活[2]。 Istiratumab (500 nM，24 小时) 抑制具有激活 KRAS 突变的胰腺癌细胞中 IGF-1 和 HRG 诱导的 AKT 磷酸化[2]。 Istiratumab (500 nM, 24 h) 通过蛋白酶体途径诱导 IGF-1R 和 ErbB3 受体降解[2]。 Istiratumab (1 μM，60 分钟) 阻断卵巢癌细胞系中 PI3K 和 MAPK 信号级联的激活[3]。 Western Blot Analysis[2] Cell Line: AsPC1, BxPC3, Capan2, CFPAC1, etc. Concentration: 500 nM Incubation Time: 24 h Result: Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines. |
| References |
| No Any Chemical & Physical Properties |